Company news

Angiodynamics, Inc. (NASDAQ:ANGO) news

Every Angiodynamics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.

View Angiodynamics, Inc. →

Press releases — page 2

AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions

May 6, 2024

AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture

April 4, 2024

AngioDynamics Receives 510(k) Clearance for AlphaVac F18⁸⁵ System in Treatment of PE

April 4, 2024

AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.

April 1, 2024

AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024

March 19, 2024

AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference

March 6, 2024

AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million

February 15, 2024

AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease

January 23, 2024

AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance

January 5, 2024

AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024

December 7, 2023

AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism

December 7, 2023

AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance

October 4, 2023

AngioDynamics to Report Fiscal 2024 First Quarter Financial Results on October 4, 2023

September 12, 2023

AngioDynamics Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation

August 15, 2023

AngioDynamics Completes Enrollment for PRESERVE Clinical Study

August 3, 2023

AngioDynamics to Participate in a Fireside Chat at the Canaccord Genuity Growth Conference

July 31, 2023

AngioDynamics Announces Addition of Lorinda Burgess to Board of Directors

July 24, 2023

AngioDynamics Reports Fiscal Year 2023 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2024 Guidance

July 12, 2023

AngioDynamics to Report Fiscal 2023 Fourth Quarter and Full-Year Financial Results on July 12, 2023

June 20, 2023

AngioDynamics Announces Sale of Dialysis Product Portfolio and BioSentry Product to Merit Medical Systems for $100 Million

June 8, 2023

AngioDynamics to Present at the Needham Virtual Healthcare Conference

April 11, 2023

AngioDynamics Reports Fiscal 2023 Third Quarter Financial Results; Revises Guidance

March 30, 2023

AngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023

March 13, 2023

AngioDynamics to Participate in Three Investor Conferences in March

February 28, 2023

AngioDynamics Reports Fiscal 2023 Second Quarter Financial Results; Reaffirms Guidance

January 5, 2023

AngioDynamics to Report Fiscal 2023 Second Quarter Financial Results on January 5, 2023

December 15, 2022

AngioDynamics to Present at the Piper Sandler Healthcare Conference

November 17, 2022

AngioDynamics Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F18⁸⁵ PE System in Treatment of Pulmonary Embolism

October 31, 2022

AngioDynamics Reports Fiscal 2023 First Quarter Financial Results; Reaffirms Guidance

October 6, 2022

AngioDynamics to Report Fiscal 2023 First Quarter Financial Results on October 6, 2022

September 8, 2022

AngioDynamics to Present at the Canaccord Genuity Growth Conference

August 3, 2022

AngioDynamics Reports Fiscal Year 2022 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2023 Guidance

July 12, 2022

AngioDynamics to Report Fiscal 2022 Fourth Quarter and Full-Year Financial Results on July 12, 2022

June 15, 2022

AngioDynamics to Present at the UBS Global Healthcare Conference

May 16, 2022

AngioDynamics to Present at the BofA Securities Healthcare Conference

May 3, 2022

AngioDynamics Reports Fiscal 2022 Third Quarter Financial Results; Reaffirms Fiscal Year 2022 Guidance

April 7, 2022

AngioDynamics to Report Fiscal 2022 Third Quarter Financial Results on April 7, 2022

March 14, 2022

AngioDynamics to Present at Three Investor Conferences in March

March 8, 2022

PAVmed Appoints Shaun O’Neil as Chief Operating Officer

February 24, 2022

AngioDynamics to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

February 8, 2022

AngioDynamics Reports Fiscal 2022 Second Quarter Financial Results; Reaffirms Revenue Guidance; Revises Gross Margin and Adjusted EPS Guidance

January 6, 2022

AngioDynamics to Present at the Needham Virtual Growth Conference

January 3, 2022

AngioDynamics to Report Fiscal 2022 Second Quarter Financial Results on January 6, 2022

December 15, 2021

AngioDynamics Reports Fiscal 2022 First Quarter Financial Results; Updates Guidance

September 30, 2021

AngioDynamics to Report Fiscal 2022 First Quarter Financial Results on September 30, 2021

September 15, 2021

AngioDynamics to Present at the Canaccord Genuity Virtual Growth Conference

July 29, 2021

AngioDynamics Reports Fiscal 2021 Fourth Quarter and Full-Year Financial Results

July 13, 2021

AngioDynamics Announces Details for Investor & Technology Day on July 13, 2021

July 8, 2021

AngioDynamics to Report Fiscal 2021 Fourth Quarter and Full-Year Financial Results and Host Investor & Technology Day on July 13, 2021

June 24, 2021

AngioDynamics Receives 510(k) Clearance for AlphaVac Mechanical Thrombectomy System

June 8, 2021

← Newer · Older →